Filing search / Tempest Therapeutics, Inc. / "Leadership" / Page 3

8-K

EX-99.3

or4tsrb ku74tdscud

9 Aug 18

OvaScience and Millendo Therapeutics Announce Merger to Create Leading Rare Endocrine Disease Company

5:19pm

8-K

EX-99.1

1ehinc e3kbi7i58

9 Aug 18

OvaScience and Millendo Therapeutics Announce Merger to Create Leading Rare Endocrine Disease Company

5:19pm

8-K

EX-99.2

vlbxc97

9 Aug 18

OvaScience and Millendo Therapeutics Announce Merger to Create Leading Rare Endocrine Disease Company

5:19pm

425

EX-99.2

jrixozapmm

9 Aug 18

Business combination disclosure

5:17pm

425

EX-99.1

6ypapvjxfza

9 Aug 18

Business combination disclosure

5:17pm

425

EX-99.3

6lec7k

9 Aug 18

Business combination disclosure

5:17pm

8-K

EX-99.1

pd4bjk3

3 May 18

OvaScience Reports First Quarter 2018 Financial Results and Provides Business Update

4:53pm

8-K

EX-99.1

txpmn wub

11 Dec 14

OvaScience Strengthens Management Team to Support Expanding

12:00am

424B3

801ejom8raefhc80vi40

3 May 13

Prospectus supplement

12:00am

DEF 14A

hn93zgunsa

26 Apr 13

Definitive proxy

12:00am